Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer

Cancer Chemother Pharmacol. 2019 Oct;84(4):669-677. doi: 10.1007/s00280-019-03887-2. Epub 2019 Jun 11.


Gastric cancer (GC) is the third cause of cancer-related death worldwide. Patients with unresectable GC can be treated with chemotherapy such as paclitaxel, which is a microtubule stabilizer. The use of nanoparticle albumin-bound paclitaxel (nab-ptx) avoids hypersensitivity reactions due to the absence of solvent needed to dissolve paclitaxel and it can be administered at higher doses. The ABSOLUTE randomized phase-3 clinical trial showed the non-inferiority of the nab-ptx used every week compared to the solvent-based paclitaxel used every week. This review describes the current advancements of the use of nab-ptx in GC in preclinical and clinical study investigations. The possibility of combining nab-ptx with other medications to improve response of patients to their specific molecular needs will also be debated.

Keywords: Nab-paclitaxel; Nanoparticle; Paclitaxel; Ramucirumab.

Publication types

  • Review

MeSH terms

  • Albumin-Bound Paclitaxel / pharmacology*
  • Humans
  • Nanoparticles / therapeutic use
  • Stomach Neoplasms / drug therapy*
  • Tubulin Modulators / pharmacology


  • Albumin-Bound Paclitaxel
  • Tubulin Modulators